Federal IDR outcomes: Intraoperative neuromonitoring in Hawaii
In 2025 Q1–Q4, the provider or facility offer prevailed in 89.4% of 151 determined Federal IDR dispute line items for intraoperative neuromonitoring in Hawaii. The median prevailing offer was 13.69x the QPA (25th–75th percentile 7.32x–27.09x; n = 151). The median time to a decision was 26 business days (n = 151).
Determined line items
151
2025 Q1–Q4 · 0 split decisions excluded
Provider win rate
89.4%
n = 151 · 2025 Q1–Q4
Median payment vs QPA
13.69x
middle half 7.32x–27.09x · n = 151 · 2025 Q1–Q4
Median days to decision
26
business days, from dispute initiation · n = 151 · 2025 Q1–Q4
Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 151 | 89.4% | 13.69x | 7.32x–27.09x | 151 | 26 |
| 2024 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2023 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2023 Q1–2025 Q4 | 186 | 89.2% | 13.69x | 5.50x–26.97x | 186 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
Most disputed CPT codes
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 95938 Placement of skin electrodes and measurement of stimulated sites on arms and leg | 35 | 88.6% | 36.98x † | 35 | 27 |
| 95861 Needle measurement of electrical activity in arm or leg muscles, 2 extremities | 33 | 84.8% | 9.82x | 33 | 26 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Related: all specialties in Hawaii · Intraoperative neuromonitoring in all states
FAQ
What is the Federal IDR provider win rate for intraoperative neuromonitoring in Hawaii?
In 2025 Q1–Q4, the provider or facility offer was selected in 89.4% of 151 determined dispute line items for intraoperative neuromonitoring in Hawaii. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.
How do Federal IDR payments compare with the QPA for intraoperative neuromonitoring in Hawaii?
In 2025 Q1–Q4, the median prevailing offer was 13.69x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 7.32x to 27.09x (n = 151 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.
How long do Federal IDR decisions take for intraoperative neuromonitoring in Hawaii?
In 2025 Q1–Q4, the median was 26 business days (n = 151 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).